TY - JOUR
T1 - Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma
AU - Du, Lingling
AU - DeFoe, Melissa
AU - Ruzinova, Marianna B.
AU - Olsen, Jeffrey R.
AU - Wang-Gillam, Andrea
N1 - Funding Information:
This publication was supported by the Washington University Institute of Clinical and Translational Sciences grants UL1 TR000448 and KL2 TR000450 from the National Center for Advancing Translational Sciences . The content is solely the responsibility of the authors and does not necessarily represent official views of the National Institutes of Health.
Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - It is estimated that 10% to 20% of patients with pancreatic cancer present with resectable disease. Although surgery offers curative intent, the median survival after curative resection is less than 2 years. To improve clinical outcomes in this patient population, clinical studies have investigated the role of perioperative therapy, including neoadjuvant and adjuvant treatment in resectable pancreatic cancer. The role of adjuvant therapy has been well established by large randomized phase III studies, whereas benefit of the neoadjuvant approach remains inconclusive. Here, we review various treatment modalities and their clinical benefits in resectable pancreatic cancer.
AB - It is estimated that 10% to 20% of patients with pancreatic cancer present with resectable disease. Although surgery offers curative intent, the median survival after curative resection is less than 2 years. To improve clinical outcomes in this patient population, clinical studies have investigated the role of perioperative therapy, including neoadjuvant and adjuvant treatment in resectable pancreatic cancer. The role of adjuvant therapy has been well established by large randomized phase III studies, whereas benefit of the neoadjuvant approach remains inconclusive. Here, we review various treatment modalities and their clinical benefits in resectable pancreatic cancer.
KW - Adjuvant therapy
KW - HENT1
KW - Neoadjuvant therapy
KW - Predictive biomarkers
KW - Resectable pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=84938201822&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2015.04.011
DO - 10.1016/j.hoc.2015.04.011
M3 - Review article
C2 - 26226906
AN - SCOPUS:84938201822
SN - 0889-8588
VL - 29
SP - 717
EP - 726
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 4
ER -